In addition, FLT3 expression hardly affected cell cycle distribution or cell proliferation, suggesting that, apart from its role in AML, FLT3 does not endow CML cells with growth advantages (Fig. S1A and B). Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.